Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics.

Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 9607880 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2092-6413 (Electronic) Linking ISSN: 12263613 NLM ISO Abbreviation: Exp Mol Med Subsets: MEDLINE

Publication: Jan. 2013- : New York : Nature Publishing Group
Original Publication: Seoul : Korean Society of Medical Biochemistry and Molecular Biology, 1996-

Extracellular Vesicles*/metabolism ; Extracellular Vesicles*/immunology ; Immune Checkpoint Proteins*/metabolism ; Neoplasms*/drug therapy ; Neoplasms*/immunology ; Neoplasms*/metabolism ; Neoplasms*/pathology ; Tumor Microenvironment*/immunology; Animals ; Humans ; Cell Communication/immunology ; Immune Checkpoint Inhibitors/therapeutic use ; Immunomodulation

Immune checkpoint proteins (ICPs) serve as critical regulators of the immune system, ensuring protection against damage due to overly activated immune responses. However, within the tumor environment, excessive ICP activation weakens antitumor immunity. Despite the development of numerous immune checkpoint blockade (ICB) drugs in recent years, their broad application has been inhibited by uncertainties about their clinical efficacy. A thorough understanding of ICP regulation in the tumor microenvironment is essential for advancing the development of more effective and safer ICB therapies. Extracellular vesicles (EVs), which are pivotal mediators of cell-cell communication, have been extensively studied and found to play key roles in the functionality of ICPs. Nonetheless, a comprehensive review summarizing the current knowledge about the crosstalk between EVs and ICPs in the tumor environment is lacking. In this review, we summarize the interactions between EVs and several widely studied ICPs as well as their potential clinical implications, providing a theoretical basis for further investigation of EV-related ICB therapeutic approaches.
Competing Interests: Competing interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.
(© 2024. The Author(s).)

Cell Rep. 2015 Oct 13;13(2):412-24. (PMID: 26411680)
Mol Cancer. 2022 Jan 18;21(1):20. (PMID: 35042524)
Mol Cancer Res. 2024 Feb 1;22(2):125-136. (PMID: 37889101)
Blood. 2012 Apr 19;119(16):3734-43. (PMID: 22383801)
Arch Med Res. 2021 Feb;52(2):200-210. (PMID: 33162186)
J Exp Clin Cancer Res. 2022 Jan 27;41(1):41. (PMID: 35086548)
Nat Commun. 2019 Mar 27;10(1):1387. (PMID: 30918259)
J Immunother. 2024 Feb-Mar 01;47(2):64-76. (PMID: 38047403)
Anal Chim Acta. 2023 Apr 22;1251:340984. (PMID: 36925282)
Cell Commun Signal. 2022 Jan 28;20(1):12. (PMID: 35090495)
Mol Cancer Ther. 2019 Nov;18(11):2051-2062. (PMID: 31395688)
Cell Res. 2018 Aug;28(8):862-864. (PMID: 29959401)
Thorac Cancer. 2020 Jun;11(6):1453-1464. (PMID: 32212417)
Diagn Pathol. 2021 Oct 25;16(1):94. (PMID: 34689789)
Oncoimmunology. 2022 Dec 26;12(1):2152635. (PMID: 36605619)
Mol Cancer. 2023 Nov 30;22(1):193. (PMID: 38037077)
Cell Commun Signal. 2022 Jan 28;20(1):14. (PMID: 35090497)
Int J Oncol. 2023 Sep;63(3):. (PMID: 37503786)
J Exp Med. 2019 Apr 1;216(4):982-1000. (PMID: 30872362)
Front Immunol. 2020 Dec 15;11:608024. (PMID: 33384695)
J Nanobiotechnology. 2020 Oct 22;18(1):151. (PMID: 33092576)
Br J Cancer. 2020 Mar;122(5):640-647. (PMID: 31853007)
Front Immunol. 2020 Apr 07;11:604. (PMID: 32322256)
Theranostics. 2022 Jan 31;12(5):1971-1987. (PMID: 35265193)
Immunity. 2015 Feb 17;42(2):239-251. (PMID: 25692700)
Cancer Cell Int. 2023 Jul 14;23(1):137. (PMID: 37452413)
Cancer Sci. 2023 Oct;114(10):3857-3872. (PMID: 37525561)
Clin Exp Immunol. 2024 Mar 12;216(1):68-79. (PMID: 38146642)
Biomolecules. 2021 Oct 29;11(11):. (PMID: 34827604)
Transl Oncol. 2022 Apr;18:101334. (PMID: 35093790)
Immunity. 2022 May 10;55(5):912-924.e8. (PMID: 35413245)
Oncogenesis. 2020 Jul 6;9(7):65. (PMID: 32632113)
Cancer Immunol Immunother. 2023 Mar;72(3):743-758. (PMID: 36319716)
Arterioscler Thromb Vasc Biol. 2018 Jul;38(7):1479-1492. (PMID: 29794115)
Blood Adv. 2022 Mar 22;6(6):1879-1894. (PMID: 35130345)
J Immunother Cancer. 2021 Jan;9(1):. (PMID: 33472857)
N Engl J Med. 2010 Aug 19;363(8):711-23. (PMID: 20525992)
Nat Rev Immunol. 2022 Sep;22(9):567-575. (PMID: 35277664)
Sci Rep. 2023 Jan 10;13(1):463. (PMID: 36627334)
Pharmacol Res. 2023 Sep;195:106871. (PMID: 37506784)
Cancer Res. 2006 May 1;66(9):4795-801. (PMID: 16651434)
Biosens Bioelectron. 2020 Jan 15;148:111800. (PMID: 31678824)
J Extracell Vesicles. 2024 Aug;13(8):e12472. (PMID: 39092563)
Mol Ther Nucleic Acids. 2024 Jan 23;35(1):102125. (PMID: 38356866)
Neurooncol Adv. 2022 Feb 15;4(1):vdac017. (PMID: 35990703)
Small Methods. 2022 Sep;6(9):e2200549. (PMID: 35810463)
Biochem Biophys Res Commun. 2018 Apr 6;498(3):409-415. (PMID: 29452091)
BMC Cancer. 2023 May 1;23(1):389. (PMID: 37127565)
Angew Chem Int Ed Engl. 2021 Mar 29;60(14):7582-7586. (PMID: 33382182)
Immunol Rev. 2009 May;229(1):12-26. (PMID: 19426212)
Biosens Bioelectron. 2022 Nov 15;216:114636. (PMID: 35986985)
Cell Death Dis. 2020 Nov 6;11(11):955. (PMID: 33159034)
Nat Nanotechnol. 2021 Jan;16(1):37-46. (PMID: 33349685)
Br J Cancer. 2024 Jan;130(1):63-72. (PMID: 37973956)
Semin Cancer Biol. 2022 Nov;86(Pt 3):137-150. (PMID: 35341913)
Elife. 2019 Aug 30;8:. (PMID: 31469364)
Mol Cancer. 2022 Mar 16;21(1):75. (PMID: 35296335)
Nat Rev Clin Oncol. 2018 Oct;15(10):617-638. (PMID: 29795272)
ACS Nano. 2023 Jun 13;17(11):10637-10650. (PMID: 37213184)
J Hematol Oncol. 2019 Sep 5;12(1):92. (PMID: 31488176)
Dev Cell. 2022 Feb 7;57(3):329-343.e7. (PMID: 35085484)
Semin Cancer Biol. 2023 Nov;96:36-47. (PMID: 37748738)
Cancer Metastasis Rev. 2024 Jun;43(2):575-595. (PMID: 37851319)
Int J Mol Sci. 2021 Mar 30;22(7):. (PMID: 33808435)
Heliyon. 2023 Dec 02;9(12):e23171. (PMID: 38144305)
Front Cell Dev Biol. 2021 Mar 01;9:629893. (PMID: 33732698)
Blood. 2022 Jun 23;139(25):3617-3629. (PMID: 35344582)
Front Genet. 2022 Aug 23;13:965329. (PMID: 36081999)
Nat Commun. 2017 May 16;8:15287. (PMID: 28508895)
Biosens Bioelectron. 2022 Apr 1;201:113954. (PMID: 35030466)
Anal Chem. 2023 Dec 12;95(49):18268-18277. (PMID: 38011622)
Clin Cancer Res. 2018 Feb 15;24(4):896-905. (PMID: 29233903)
J Clin Endocrinol Metab. 2024 Mar 15;109(4):1132-1144. (PMID: 37967245)
Clin Cancer Res. 2010 May 15;16(10):2861-71. (PMID: 20460488)
Cell Death Differ. 2023 Oct;30(10):2265-2279. (PMID: 37648786)
Angew Chem Int Ed Engl. 2020 Mar 16;59(12):4800-4805. (PMID: 31912940)
Cancer Immunol Immunother. 2023 Nov;72(11):3727-3738. (PMID: 37665374)
Clin Exp Immunol. 2022 Jun 23;208(3):316-322. (PMID: 35514075)
Immunol Rev. 2021 Jul;302(1):32-46. (PMID: 34046914)
Front Oncol. 2020 May 27;10:760. (PMID: 32528882)
Anticancer Drugs. 2022 Jan 1;33(1):e381-e388. (PMID: 34419956)
BMC Cancer. 2021 Aug 19;21(1):933. (PMID: 34412616)
Virol J. 2024 Jan 30;21(1):34. (PMID: 38291452)
J Hematol Oncol. 2023 Sep 5;16(1):101. (PMID: 37670328)
Anal Chem. 2023 Jan 17;95(2):1016-1026. (PMID: 36534080)
Cell Commun Signal. 2021 Apr 23;19(1):47. (PMID: 33892745)
Cell Rep. 2017 Aug 1;20(5):1017-1028. (PMID: 28768188)
Nature. 2018 Aug;560(7718):382-386. (PMID: 30089911)
Clin Cancer Res. 2022 Dec 1;28(23):5030-5039. (PMID: 35579997)
Nat Commun. 2016 Nov 24;7:13588. (PMID: 27882925)
Cancer Immunol Immunother. 2021 May;70(5):1213-1226. (PMID: 33119798)
Cell Tissue Res. 2022 Sep;389(3):465-481. (PMID: 35688948)
Cancers (Basel). 2022 Aug 28;14(17):. (PMID: 36077704)
Cell Signal. 2023 Sep;109:110737. (PMID: 37263461)
Immunity. 2024 Feb 13;57(2):206-222. (PMID: 38354701)
Hepatology. 2019 Jul;70(1):241-258. (PMID: 30854665)
Oral Oncol. 2023 Oct;145:106524. (PMID: 37482043)
Cell Rep Med. 2023 Sep 19;4(9):101171. (PMID: 37657445)
Endocr Metab Immune Disord Drug Targets. 2023;23(11):1410-1420. (PMID: 36852791)
Cytokine Growth Factor Rev. 2023 Oct;73:135-149. (PMID: 37543438)
iScience. 2023 Nov 09;26(12):108414. (PMID: 38047083)
Cell Biosci. 2021 Mar 31;11(1):63. (PMID: 33789726)
Front Pharmacol. 2023 Aug 03;14:1159829. (PMID: 37601051)
Front Cell Dev Biol. 2021 Jul 19;9:653808. (PMID: 34350172)
Cancers (Basel). 2023 May 16;15(10):. (PMID: 37345111)
Nat Commun. 2018 May 15;9(1):1908. (PMID: 29765039)
Oral Dis. 2024 May;30(4):2039-2050. (PMID: 37649401)
Cancer Cell Int. 2023 Oct 26;23(1):252. (PMID: 37884996)
Mol Cancer. 2023 Dec 13;22(1):203. (PMID: 38087360)
Adv Sci (Weinh). 2022 Jan 17;9(9):2102620. (PMID: 35356153)
Genomics. 2023 Jul;115(4):110646. (PMID: 37217085)
J Nanobiotechnology. 2023 Mar 11;21(1):86. (PMID: 36906540)
ACS Sens. 2021 Sep 24;6(9):3308-3319. (PMID: 34494426)
Mol Ther. 2023 Dec 6;31(12):3579-3593. (PMID: 37919900)
Science. 2018 Oct 12;362(6411):. (PMID: 30309915)
Nat Immunol. 2013 Feb;14(2):152-61. (PMID: 23242415)
Ann Hematol. 2023 Sep;102(9):2435-2444. (PMID: 37162517)
Mol Cell Endocrinol. 2023 Jun 1;568-569:111917. (PMID: 37028587)
Cancer Immunol Res. 2015 Apr;3(4):412-23. (PMID: 25691328)
Adv Sci (Weinh). 2023 Feb;10(6):e2206411. (PMID: 36567273)
Genes Dis. 2023 Mar 24;11(1):321-334. (PMID: 37588227)
Fundam Clin Pharmacol. 2024 Apr;38(2):369-379. (PMID: 38012082)
Signal Transduct Target Ther. 2021 Nov 19;6(1):397. (PMID: 34795203)
Oral Oncol. 2023 Oct;145:106532. (PMID: 37499326)
Cell Death Discov. 2022 Apr 23;8(1):223. (PMID: 35461336)
Cancer Med. 2022 Jul;11(13):2627-2643. (PMID: 35347894)
Mol Cancer. 2023 Aug 18;22(1):138. (PMID: 37596643)
Biochem Biophys Res Commun. 2016 Nov 11;480(2):166-172. (PMID: 27725157)
Cancer Lett. 2021 Mar 1;500:98-106. (PMID: 33307156)
Methods Mol Biol. 2023;2695:195-212. (PMID: 37450120)
Int Immunopharmacol. 2022 Dec;113(Pt A):109320. (PMID: 36274482)
Cell Commun Signal. 2023 Sep 21;21(1):246. (PMID: 37735659)
Cancer Immunol Res. 2023 Feb 3;11(2):217-227. (PMID: 36546872)
Nat Commun. 2016 Aug 30;7:12632. (PMID: 27572267)
Cell Commun Signal. 2024 Jan 9;22(1):21. (PMID: 38195554)
Cancer Immunol Immunother. 2023 Dec;72(12):4249-4259. (PMID: 37943341)
Clin Cancer Res. 2023 Feb 1;29(3):659-666. (PMID: 36374561)
Cancer Med. 2023 Aug;12(15):16405-16415. (PMID: 37501397)
Front Oncol. 2023 Jul 28;13:1233376. (PMID: 37614504)
Med Oncol. 2023 Jul 4;40(8):221. (PMID: 37402056)
Mol Cancer. 2021 May 29;20(1):80. (PMID: 34051805)
Cancers (Basel). 2024 Jan 12;16(2):. (PMID: 38254825)
Nat Immunol. 2012 Sep;13(9):832-42. (PMID: 22842346)
Front Immunol. 2023 Jan 18;13:1097117. (PMID: 36741391)
J Extracell Vesicles. 2018 Nov 23;7(1):1535750. (PMID: 30637094)
J Clin Invest. 2016 Dec 1;126(12):4537-4553. (PMID: 27797340)
Mol Cancer. 2020 Jun 27;19(1):110. (PMID: 32593303)
Clin Cancer Res. 2016 Jul 15;22(14):3425-3431. (PMID: 27208063)
Nat Protoc. 2023 May;18(5):1462-1487. (PMID: 36914899)
Front Oncol. 2021 May 17;11:670490. (PMID: 34079761)
Nat Rev Immunol. 2020 Mar;20(3):173-185. (PMID: 31676858)
Cell Res. 2020 Aug;30(8):660-669. (PMID: 32467592)
Oncogene. 2021 Aug;40(31):4992-5001. (PMID: 34172932)
NPJ Precis Oncol. 2022 Jun 21;6(1):42. (PMID: 35729210)
Cell Death Dis. 2023 Sep 4;14(9):586. (PMID: 37666809)
Angew Chem Int Ed Engl. 2021 Aug 9;60(33):18111-18115. (PMID: 34043264)
Sci Rep. 2021 Apr 9;11(1):7830. (PMID: 33837261)
Adv Sci (Weinh). 2022 Feb;9(5):e2103245. (PMID: 34927389)
Nat Commun. 2016 Feb 17;7:10501. (PMID: 26883990)
Semin Oncol. 2010 Oct;37(5):430-9. (PMID: 21074057)
Biochim Biophys Acta Rev Cancer. 2024 Mar;1879(2):189058. (PMID: 38113952)
J Transl Med. 2024 Mar 11;22(1):267. (PMID: 38468343)
J Investig Med. 2024 Jan;72(1):57-66. (PMID: 37804164)
Cell Mol Immunol. 2022 Nov;19(11):1290-1301. (PMID: 36220994)
Front Med. 2024 Feb;18(1):128-146. (PMID: 37870681)
Front Pharmacol. 2021 Oct 20;12:757194. (PMID: 34744733)
Small. 2023 Sep;19(37):e2300527. (PMID: 37226374)
Nat Commun. 2023 Oct 28;14(1):6883. (PMID: 37898620)
Biosci Trends. 2022 Sep 17;16(4):267-281. (PMID: 35934785)
Biochem Biophys Rep. 2023 Oct 05;36:101542. (PMID: 37822876)
J Exp Med. 1991 Sep 1;174(3):561-9. (PMID: 1714933)
Oncol Rep. 2021 Mar;45(3):801-808. (PMID: 33469681)
NPJ Syst Biol Appl. 2023 Dec 12;9(1):61. (PMID: 38086828)
Oncoimmunology. 2021 Oct 29;10(1):1995166. (PMID: 34745768)
Science. 2018 Mar 23;359(6382):1350-1355. (PMID: 29567705)
Int J Mol Sci. 2020 Sep 25;21(19):. (PMID: 32992699)
Acta Biomater. 2020 Oct 1;115:371-382. (PMID: 32798721)
Cell. 2017 Feb 9;168(4):692-706. (PMID: 28187289)
Endocrinol Metab (Seoul). 2023 Dec;38(6):750-759. (PMID: 37956967)
Front Immunol. 2021 Oct 01;12:736030. (PMID: 34659224)
Transl Oncol. 2023 Jan;27:101564. (PMID: 36252282)
J Cell Commun Signal. 2020 Dec;14(4):389-402. (PMID: 32157550)
J Extracell Vesicles. 2023 Dec;12(12):e12390. (PMID: 38117000)
Lancet Oncol. 2018 Feb;19(2):229-239. (PMID: 29361469)
Immunity. 2021 Jun 8;54(6):1154-1167.e7. (PMID: 33979578)
Biomedicines. 2023 Jul 18;11(7):. (PMID: 37509655)
Commun Biol. 2023 Aug 4;6(1):815. (PMID: 37542121)
Cell Rep. 2016 Sep 13;16(11):2914-2927. (PMID: 27626662)
Cell. 2019 Apr 4;177(2):414-427.e13. (PMID: 30951669)
Mil Med Res. 2021 Nov 8;8(1):56. (PMID: 34743730)
Nat Rev Immunol. 2023 Oct;23(10):682-695. (PMID: 37185300)
Anal Chem. 2023 May 2;95(17):6854-6862. (PMID: 37027485)
J Immunol. 2014 Jan 15;192(2):782-91. (PMID: 24337741)
Clin Chem. 2024 Jan 4;70(1):206-219. (PMID: 38175602)
ESMO Open. 2020 Jan;5(1):. (PMID: 32516116)
Cell. 2019 Jan 10;176(1-2):334-347.e12. (PMID: 30580966)
Cancers (Basel). 2020 Jul 29;12(8):. (PMID: 32751214)
Cancers (Basel). 2021 Jul 10;13(14):. (PMID: 34298673)
Cancer Immunol Res. 2017 Dec;5(12):1141-1151. (PMID: 29097421)
Cancer Treat Rev. 2023 Nov;120:102614. (PMID: 37603905)
Nat Immunol. 2023 Sep;24(9):1415-1422. (PMID: 37488429)

82173245 National Natural Science Foundation of China (National Science Foundation of China); 82300881 National Natural Science Foundation of China (National Science Foundation of China)

0 (Immune Checkpoint Inhibitors)
0 (Immune Checkpoint Proteins)

Date Created: 20241111 Date Completed: 20241202 Latest Revision: 20241211

20241212

PMC11612210

10.1038/s12276-024-01340-w

39528800